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INTRODUCTION 1 2
The complement system constitutes a complex group of both soluble and cell-associated proteins 3 that together form an integral part of the innate host defense against pathogens (reviewed in 18). 4
Complement can serve to link innate and adaptive immunity to viruses through a large number of 5 activities, including recognition of virions, direct neutralization of infectivity, recruitment and stimulation 6 of leukocytes, opsonization by immune cells, and activation of T and B cell responses (4, 10) . 7
Complement activation can play important roles in viral pathogenesis (e.g., 24), and has been the focus of 8 efforts to improve the effectiveness of vaccines and therapeutic vectors (31) . The goal of the work 9 described here was to determine the role of human complement in neutralization of the paramyxovirus 10 Nipah virus (NiV), an emerging human pathogen with no currently available vaccines or therapeutics. 11
The complement cascade can be initiated through three main pathways: the classical pathway, 12 lectin pathway or alternative pathway (10, 30) . These three pathways converge on a central component 13 C3, which is activated by cleavage into the anaphylatoxin C3a and C3b which can bind covalently to viral 14 components to aid in opsonization and phagocytosis. The association of C3b with further downstream 15 components such as C6 through C9 can lead to formation of the membrane attack complex (MAC) which 16 is capable of lysing virus particles or infected cells (reviewed in 4, 10). The classical pathway, which is 17 activated by antibodies, and the lectin pathway, which is activated by carbohydrate structures, converge 18 on C4 which is cleaved into the anaphylatoxin C4a and the C4b fragment. Together with C3b, this can 19 also lead to downstream activation of MAC. 20 We and others have previously shown that the paramyxoviruses Parainfluenza Virus 5 (PIV5) and 21 mumps virus (MuV) activate the alternative complement pathway and that activation of complement 22 component C3 is essential for effective in vitro neutralization by normal human serum (NHS; 16, 17, 26) . 23 on October 20, 2017 by guest http://jvi.asm.org/ Downloaded from 12 volumes were similar to that of the C3a ELISA. ELISA was performed as described by the manufacturers: 13
MicrocroVue Bb kit from Quidel (San Diego, CA), or OptEIA Human C3a and C4a kit from BD 14 Biosciences (San Jose, CA). Statistical significance was determined using Student's t test. 15 Time or concentration dependent activation of C3 by NiVpp was assayed by Western blot 16 analysis. For the concentration experiment, NiVpp was diluted 2 fold with the highest concentration being 17 1.5 X 10 5 genome copies and incubated for 1 h with NHS (1:10) at 37 O C. For the timecourse experiment, 18 7.5 X 10 3 genome copies were incubated for varying times with NHS (1:10) at 37 O C. The samples were 19 separated on a 15% SDS PAGE gel, and analyzed by western blotting using rabbit anti-human C3a 20
(1:2000 dilution) followed by anti-rabbit HRP (Biorad). Blots were visualized by horseradish peroxidase-21 conjugated antibodies and enhanced chemiluminescence (Pierce Chemicals). 22 on October 20, 2017 by guest http://jvi.asm.org/ Downloaded from 7 Electron microscopy. C3 deposition on NiVpps was analyzed by adsorbing 1.5 X 10 5 genome 1 copies of purified particles on carbon-coated 200 mesh gold grids (Electron Microscopy Sciences, PA) 2 followed by a 5 min incubation at room temperature in a humidified chamber. The particles were either 3 treated with polyclonal anti-Nipah F and G antibody at a dilution of 1:3200 or left untreated. After 4 treatment with NHS (1:10 dilution), samples were blocked with 1% BSA in PBS and then probed with 5 anti-C3 monoclonal antibody (Cell Sciences) at a dilution of 1 ug in 10 ul. Deposition was detected with 6 12 nm gold labeled goat anti-rabbit antibody and 6 nm gold labeled goat anti-mouse antibodies (Jackson 7
Immunoresearch Laboratories, PA). C1q association was analyzed using primary goat anti-C1q antibody 8
(1:25) and 6 nm gold-labeled donkey anti-goat secondary antibody. After labeling, particles were 9 subjected to negative staining with 2% phosphotungstic acid (pH 6.6) and analyzed with a Philips 10 TEM400 transmission electron microscope as previously described (16). physiological concentrations of the depleted factor was reconstituted as described previously (17). 17
Samples were diluted to 250 ul in PBS with 1% FBS and used to infect Vero cell monolayers in 24 well 18 plates for 2 h at 37 O C. Cells were then rinsed with PBS and incubated for 24 h before analysis using a 19 Renilla luciferase assay system (Promega). In some experiments, NiVpp was incubated with anti-G and 20 anti-F antibody or with EphB2-Fc in the presence or absence of NHS for 1 h prior to assay for infectivity 21 as described in the figure legends. Statistical significance was determined using Student's t test. Pseudotypes containing the NiV glycoproteins activate the alternative arm of the 2 complement pathway. Due to the constraints of working with BSL-4 live NiV, pseudotyped reporter 3 viruses (NiVpp) were generated to contain the NiV glycoproteins F and G in an envelope surrounding a 4 VSV genome that encodes the Renilla luciferase gene in place of the VSV G glycoprotein gene (1). These 5 single cycle pseudotypes were purified by centrifugation and used in assays for interactions with 6 complement factors. To determine if the NiVpp activated human complement pathways, increasing levels 7 of NiVpp were incubated with NHS and then assayed by western blotting for levels of the C3 cleavage 8 product C3a. As shown in the titration experiment in Fig. 1A , incubation of increasing levels of NiVpps 9 with NHS led to increased appearance of C3a product. Quantitation of C3a levels by ELISA showed an 10 increase in C3 activation by exposure of increasing amounts of NiVpps, starting with ~38,000 genome 11 copies ( Fig 1C) . In timecourse experiments ( Fig. 1B) , complement activation by NiVpp was rapid, with 12 the appearance of C3a cleavage products beginning by 5 min of incubation with NHS. C3a levels 13 plateaued by 15-30 min of incubation at levels which approached that seen following treatment of NHS 14 with the positive control cobra venom factor (CVF). 15
Activation of classical and lectin pathways results in the appearance of C4a cleavage product, 16
whereas activation of the alternative pathway results in cleavage of Factor B into Ba and Bb (10, 30) . 17
Using western blotting and ELISAs, we found that exposure of NiVpp to NHS did not result in 18 appearance of C4a cleavage products (data not shown), indicating that the classical/lectin arms were not 19 activated under these in vitro conditions. By contrast, NHS treatment of NiVpp resulted in the appearance 20 of the factor B cleavage product Bb (Fig. 1D) , consistent with the activation of the alternative pathway. products are deposited on virion particles (4, 16, 17) . For example, we have previously shown that 3 treatment of PIV5 with NHS results in neutralization (16, 17) . As shown in Fig. 2A , VSV-based 4 pseudotypes that contained the PIV5 glycoproteins HN and F produced high levels of luciferase activity 5 on infected Vero cells (PBS samples). Treatment with NHS prior to infection of cells led to a dramatic 6 loss of infectivity (NHS samples). Similar results were seen with NHS from a total of five separate donors 7 (not shown). Thus, the VSV-based pseudotypes containing PIV5 glycoproteins are sensitive to NHS 8 similar to that seen with bone fide PIV5 particles (16, 17) 9
To determine if activation of human complement by the NiVpp also resulted in neutralization, 10
NiVpp were incubated with dilutions of NHS or with purified antibodies specific for the NiV F and G 11 proteins as a positive control. Cells were then infected with the treated NiVpp and infectivity was 12 measured at 24 h pi by assaying luciferase levels. As shown in Fig. 2B , polyclonal antibodies to F and G 13 effectively reduced luciferase levels by ~500 fold compared to the untreated control sample. In sharp 14 contrast, results for NHS from two donors showed that there was no loss of infectivity when NiVpp were 15 incubated with NHS even at a 1:2.5 fold dilution. These data indicate that in contrast to results with PIV5 16 and mumps virus (16, 17) , complement activation does not result in neutralization of NiVpp infectivity in 17
vitro. 18
To determine if the activation of complement by NiVpp resulted in C3 deposition, NiVpp were 19 treated with NHS and examined for the presence of C3 by immunogold electron microscopy. As shown in 20 Complement enhances the potency of neutralizing anti-NiV antibodies. The above finding that C3 is 5 deposited on antibody-treated NiVpp suggested that while activated complement in NHS alone was 6 insufficient for neutralization, complement could enhance the neutralizing capacity of antibodies specific 7
for the viral glycoproteins. To test this hypothesis, NiVpp were treated for one h with dilutions of a 8 mixture of purified anti-F and anti-G polyclonal antibodies alone or in combination with NHS and 9 remaining infectivity was determined by assaying luciferase activity from infected Vero cells. As shown 10 in Fig. 3A , as the dilution of antibodies used to treat NiVpp was increased there was a corresponding 11 increase in luciferase activity, indicating reduced neutralization capacity. By contrast, in the presence of 12 NHS no luciferase activity was detected until an antibody dilution of 1:3200. In timecourse experiments, 13 treatment of NiVpp with F and G antibodies alone or in combination with NHS resulted in a rapid ~10 14 fold reduction in infectivity as soon as 1 min after incubation ( Fig. 3B ). Over time, antibody alone gave 15 only a marginal further reduction in infectivity. By contrast, samples that also contained NHS showed a 16 continuous time-dependent loss of infectivity to zero. 17
Activation of the classical pathway results in C4 cleavage. While NiVpp alone activated the 18 alternative pathway (Fig. 1) , treatment of NiVpp with both antibody and NHS resulted in the appearance 19 of C4a cleavage product ( Fig. 3C ). To determine if C4 was necessary for NHS-enhanced neutralization, 20 infectivity of NiVpp was determined after treatment with combinations of C4-depleted serum, purified 21 polyclonal anti-F and anti-G antibody, and C4-depleted serum that was reconstituted with physiological 22 levels of C4. As shown in Fig. 3D , treatment of NiVpp with C4-depleted serum (sample 2) or depleted 23 on October 20, 2017 by guest http://jvi.asm.org/ Downloaded from serum supplemented with C4 (sample 4) had only a minor effect on infectivity ( Fig. 3D ). Antibodies to 1 the NiV glycoproteins partially neutralized NiVpp (sample 1), but this was only minimally enhanced by 2 addition of C4-depleted serum (sample 3). The highest level of neutralization was seen using the 3 combined treatment with antibodies, C4-depleted serum and physiological levels of supplemented C4 4 (sample 5). These data indicate that when NiVpp are exposed to antibodies to the viral glycoproteins, C4 5 is activated and that C4 is necessary for maximal enhancement of neutralization. 6
In the case of influenza virus and West Nile virus (12, 22), C1q has been shown to be both 7 necessary and sufficient for complement-mediated enhancement of antibody neutralization. To determine 8 the role of C1q in NiV neutralization, NiVpp were treated with purified C1q in the presence or absence of 9 anti-F and anti-G antibodies and then analyzed by immunogold labeling for C1q deposition. As shown in 10 and C1q-containing serum (sample 5). These data demonstrate that neutralization of NiVpp differs from 20 that of influenza virus and West Nile virus (12, 22) in that C1q is necessary but is not by itself sufficient anti-G monoclonal antibody 213 across the entire range of concentrations tested (Fig. 5B ). As shown in 9
Table 1, three individual anti-F antibodies displayed a similar NHS-enhancement profile as that shown in 10 panel A, in which enhancement was evident only at the highest antibody concentrations. Thus, with 12.5 11 ng of the anti-F antibodies there was no enhancement of neutralization by NHS, regardless of their IC95 12 values. The anti-G antibodies behaved differently as shown in Table 1 . Three anti-G antibodies had the 13 profile shown in Fig. 5B , with enhancement at 12.5 ng of anti-G antibody ranging from 2 to 7.5 fold. 14 With these three anti-G antibodies, the level of enhancement appeared to correlate with IC95 values. 15 NHS-mediated enhancement of neutralization by anti-F and anti-G antibodies depended on both C1q and 16 C4 (data not shown). These data indicate that NHS can enhance neutralization by antibodies targeting 17 either F or G, but the extent of enhancement of an individual monoclonal antibody may depend on both 18 the target protein (e.g., F or G) and the IC95 of the particular antibody. EphrinB2, but importantly this was significantly enhanced by in the presence of NHS. It is noteworthy 4 that the effect of NHS on neutralization by various concentrations of EprhinB2 had a profile similar to 5 that seen with anti-G antibodies (Table 1) . Neutralization by soluble EphrinB2 alone was very rapid, but 6 the loss of infectivity did not change significantly with further incubation (Fig. 6B , striped bars). By 7 contrast, soluble EphrinB2 along with NHS showed a rapid initial neutralization within 1 min followed by 8 a time-dependent increased neutralization (black bars) that was not seen with soluble EphrinB2 alone. 9
Complement-mediated enhancement of EphrinB2 neutralization proceeded through the 10 classical/lectin pathway and required C4. This is evident in Fig. 6C where the C4a cleavage product 11 resulting from C4 activation was increased by exposure of NiVpp to soluble EphrinB2 and NHS. To 12 determine the role of C4 and C1q in neutralization by soluble EphrinB2, NiVpp was incubated with 13 combinations of NHS, C4-or C1q-depleted serum and physiological levels of C4 and C1q. Neutralization 14 was not enhanced by C4-depleted serum (Fig. 7, compare samples 2 and 5 ), but the combination of C4-15 depleted serum plus reconstituted C4 was equally effective as that seen with NHS ( Fig. 7, compare  16 samples 3, 5 and 7). Likewise, C1q-depleted serum did not enhance ephrin-mediated neutralization unless 17
C1q was present (Fig. 7, compare samples 9 and 11 ). Together, these data indicate that the potency of 18 soluble EphrinB2 in neutralizing NiVpp is greatly enhanced by complement components within the C1q-19 and C4-dependent pathway. The high mortality rate of NiV infections and its potential use as an agent of bioterrorism have raised 2 intense interest in developing vaccines or therapeutic approaches targeting the NiV glycoproteins (7, 8, 3 19, 29) . In view of the potent role that complement can play in paramyxovirus neutralization (16, 17, 26, 4 36) , the goal of the work described here was to determine the role of complement in neutralization of 5 particles containing the NiV glycoproteins. Our work demonstrates that exposure of the NiVpp particles 6 to NHS results in activation of the alternative complement pathway, but in contrast to findings with a 7 range of other paramyxoviruses, activation of this innate immune pathway did not result in substantial 8 neutralizing capacity. This lack of complement-mediate neutralization was not due to a global inhibition 9 of complement pathways, since addition of NHS to anti-F or anti-G antibodies increased the rate and 10 extent of neutralization by activation of the classical pathway. Our most striking finding was that 11 complement had a strong enhancing effect on neutralization by a soluble version of the EphrinB2 receptor 12 protein, resulting in very rapid and complete neutralization through activation of the classical pathway. 13
Together, these data establish the importance of complement in neutralization of particles containing the 14
NiV glycoproteins and will help guide the design of more effective therapeutics that harness the potency 15 of complement pathways. 16
Why would complement be an important factor in innate responses to NiV infections? NiV 17 infection in humans is characterized by systemic infections, where viral antigen can be detected in 18
neurons, parenchymal cells of the CNS and lymphoid tissue and in endothelial cells lining blood vessels 19
(reviewed in 7, 19). Thus, in view of targeted infections of blood vessel endothelium it is reasonable to 20 assume that NiV encounters high levels of serum complement factors during natural human infections. In 21 addition to serum, it is also clear that complement factors are produced locally during infections of organ 22 systems such as the respiratory tract. This synthesis of complement components can be from cells that are 23 on October 20, 2017 by guest http://jvi.asm.org/ Downloaded from part of the organ structure (e.g., epithelial cells), as well as immune cells recruited to the site of infection 1 (e.g., macrophages, 5). Thus, the sites of infection which include the respiratory tract, lymphoid tissue and 2 endothelial cells suggest that complement is a highly relevant innate immune pathway to consider during 3
NiV infections. 4
Previous results have shown that paramyxoviruses activate complement pathways involving either 5 alternative (16, 26) or classical pathways (33, 36) , and that NHS has strong neutralizing capacity. Similar 6 to PIV5 and MuV (16), we have found that NiVpp were strong activators of the alternative pathway. This 7 contrasts with the activation of the classical pathway by VSV (23) which forms the core particles used to 8 generate the pseudotypes, consistent with the idea that the NiV glycoproteins F and G are major 9 contributors to complement activation. In the case of PIV5 and MuV, neuraminidase activity associated 10 with the HN protein contributes to complement activation through exposure of surfaces lacking sialic acid 11 (26). As NiV glycoproteins lack neuraminidase activity, it is currently unclear what signals in F or G 12 contribute to complement activation. 13
An unexpected finding was that while PIV5 pseudotypes were neutralized by NHS as shown 14 previously for bone fide virus (Fig. 2) , the strong activation of complement by NiVpp in vitro did not 15 result in NiVpp neutralization, even in the presence of high concentrations of NHS. A similar finding 16 using normal rabbit serum was reported previously without providing data (6). The fact that C3 was not 17 stably deposited on NiVpp suggest that after activation, complement pathways are rapidly inactivated at 18 an upstream point and C3 products are prevented from forming a stable complex with particles. This 19 finding raises the possibility that NiV glycoproteins recruit host cell regulators of complement activation 20 (RCA) during the budding process (e.g., CD46) or from the fluid phase (e.g., Factor H) in order to 21 The lack of NiVpp neutralization by NHS was not due to inhibition of all complement pathways, 3 as evidence by the finding that classical pathway was activated when NHS was combined with antibody 4 specific for F or G. It is thought that C1q acts to lower the threshold for the number of antibodies needed 5 for neutralization (22) . Our results with depleted serum demonstrate that both C4 and C1q are necessary 6 but neither component was sufficient for complement-mediated enhancement of neutralization with anti-F 7 or anti-G antibodies. This insufficiency for C1q in neutralization of NiVpp contrasts with findings for 8 both influenza virus (12) and WNV (22) where C1q alone was sufficient to enhance antibody-mediated 9 neutralization. In the case of WNV, C1q-mediated complement-fixation by neutralizing antibodies does 10 not require the MAC or virolysis (21). Thus, this difference in C1q sufficiency may reflect that NiVpp 11 neutralization requires downstream factors and formation of the MAC, a proposal supported by the 12 requirement for C4 for NHS to enhance neutralization. Alternatively, this may reflect a difference in the 13 use of pseudotypes versus bone fide particles or differences in the cellular membranes from which the 14 viral envelope is derived. 15
Our results have implications for the design of more effective antibodies targeting the NiV 16 glycoproteins. Vaccination experiments have shown that protection can be conferred by anti-NiV 17 antibodies that are specific for either F or G (13, 35) . In addition, the glycosylation status of a NiV 18 glycoprotein can substantially influence antibody neutralization (1). Importantly however, to date it has 19 not been demonstrated whether complement enhances the potency of anti-F or anti-G neutralization 20 capacity. Here, titration experiments with monoclonal antibodies and soluble EphrinB2 demonstrated that 21 the ability of complement to enhance neutralization fell into one of two general profiles: 1) anti-F 22 antibodies which showed enhancement only at higher (e.g., 50 ng) but not lower antibody concentrations, 23 on October 20, 2017 by guest http://jvi.asm.org/ Downloaded from or 2) anti-G antibodies and EphrinB2 which showed enhancement at all concentrations tested including 1 very low levels of antibody (e.g., 3.1 ng) or EphrinB2 (e.g., 2.5 ng). Although only a limited number of 2 monoclonal antibodies were analyzed here, the available data suggest that the ability of complement to 3 enhance anti-F activity was relatively independent of IC95, whereas the anti-G antibodies with the lowest 4 IC95 values showed the highest level of enhancement (Table 1 ). As antibodies that show NHS-enhanced 5 neutralization at all concentrations would be the most promising agents to pursue therapeutically, future 6 work will be aimed at identifying key determinants of these antibodies (e.g., affinity, epitopes, etc) that 7 confer the highest level of interactions with complement components. For example, it may be possible to 8 select anti-NiV molecules from human antibody libraries that show the highest levels of enhancement by 9 complement components (37). 10
The identification of EphrinB2 as the NiV attachment receptor (6, 28) opened the way for the use 11 of soluble EphrinB2 as a novel receptor decoy inhibitor of NiV infections. Here we show that 12 complement components greatly enhance the potency of neutralization by a chimeric EphrinB2 molecule 13 that is fused to an IgG1 Fc domain. While soluble EphrinB2 alone produced a rapid initial neutralization 14
of NiVpp similar to that seen with antibody alone, this was followed by a further time-dependent 15 extension of neutralizating activity in the presence of complement components that acted through the 16 classical pathway. Soluble receptor decoys such as the EphrinB2-Fc chimera have several advantages 17 over conventional antibody approaches, including high affinity interactions between the attachment 18 protein and receptor and the low probability that virus will mutate to escape interactions with its receptor. 19
It may be possible in the future to engineer the EphrinB2-Fc chimera to increase its activity in recruitment 20 of complement factors as shown previously for antibody therapies (15, 27) . We thank members of the Parks and Barton labs for helpful comments on the manuscript and Ellen 3
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Remaining infectivity was determined by infection of Vero cells and assaying luciferase activity. C) 15
NiVpp were applied to carbon grids and treated with NHS or a combination of NHS and polyclonal 16 antibody specific for NiV F and G proteins as described in Materials and Methods. Samples were 17 subsequently treated with gold-conjugated anti-C3 (6 nm beads) or anti-IgG (12 nm beads) before 18 examination by electron microscopy. 19 
